Data Shows Gilead's HCV Franchise Is Surviving New Competition
March 28, 2016 at 10:47 AM EDT
Leerink’s Geoffrey C. Porges maintained an Outperform rating on Gilead Sciences, Inc. (NASDAQ: GILD), with a price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.